Serial Number
85440797
Owner
VALEANT PHARMACEUTICALS LUXEMBOURG S.À.R.LAttorney
Christopher L. GraffFiling Date
Oct 6, 2011
TESIVEE Trademark
Serial Number: 85440797
Trademark Classes
Owner Contact Info
13-15 AVENUE DE LA LIBERTÉ
LUXEMBOURG CITY 1931 , LU
Entity Type: 99
WELCHES
CHRIST CHURCH BB17154 , BB
Entity Type: 99
Legal Representation
Correspondence Address
Christopher L. Graff Pirkey Barber PLLC
60
600 Congress Avenue, Suite 2120
Austin, TX 78701
UNITED STATES
Trademark Details
Filing Date
October 6, 2011
Registration Date
Not Registered
Published for Opposition
March 4, 2014
Goods & Services
Pharmaceutical preparations and substances for the treatment of viral, metabolic, endocrine, musculoskeletal, cardiovascular, cardiopulmonary, genitourinary, sexual dysfunction, oncological, hepatological, ophthalmic, respiratory, neurological, gastrointestinal, hormonal, dermatological, psychiatric and immune system related diseases and disorders ; Pharmaceutical preparations and substances for the treatment of infectious diseases; Pharmaceutical preparations for treating allergic rhinitis and asthma; Pharmaceutical preparations and substances for use in chemotherapy; Pharmaceutical preparations and substances for use in urology; Pharmaceutical preparations and substances for the prevention, treatment and alleviation of stress; pharmaceutical preparations and substances for the prevention, treatment and alleviation of diabetes; pharmaceutical preparations and substances for controlling insulin levels; pharmaceutical preparations and substances for the prevention, treatment and alleviation of hypertension; pharmaceutical preparations and substances for the prevention, treatment and alleviation of angina; pharmaceutical preparations and substances for the cessation of smoking; pharmaceutical preparations and substances for the prevention and treatment of sexually transmitted diseases; pharmaceutical preparations and substances for the prevention and treatment of herpes; pharmaceutical preparations and substances for the prevention, treatment and alleviation of disorders, diseases, conditions and ailments of the central nervous system; pharmaceutical preparations and substances for the prevention, treatment and alleviation of depression; anti-depressants; pharmaceutical preparations and substances for the prevention, treatment and alleviation of sleep disorders; pharmaceutical preparations and substances for the prevention, treatment and alleviation of anxiety; pharmaceutical preparations and substances for the prevention, treatment and alleviation of disorders, diseases, conditions and ailments of the cardio-vascular system; pharmaceutical preparations and substances for the prevention, treatment and alleviation of acute myocardial infarctions; pharmaceutical preparations and substances for the prevention, treatment and alleviation of symptomatic congestive heart failure; pharmaceutical preparations and substances for the prevention, treatment and alleviation of asymptomatic left ventricular dysfunction; pharmaceutical preparations and substances, namely, fibrinolytic or thrombolytic agents; pharmaceutical preparations and substances for the prevention, treatment and alleviation of pain and inflammation, namely, anti-inflammatories and pain relief medication; pharmaceutical preparations and substances for the prevention, treatment and alleviation of migraines; Pharmaceutical preparations and substances for the treatment of fungal infections, onychomycosis, tinea infections, and similar diseases of the skin and nails; Pharmaceutical preparations and substances for use in dermatological conditions
